|
|
||||||||
From the Schepens Eye Research Institute, Department of Ophthalmology, Harvard Medical School, Boston, Massachusetts.
| Abstract |
|---|
|
|
|---|
METHODS. Total saliva was collected for 10 minutes from the oral cavity of male and female MRL/lpr and MRL/+ mice, after intraperitoneal stimulation with pilocarpine and isoproterenol. Lacrimal and salivary gland lobules prepared from 18-week-old MRL/lpr and MRL/+ mice were incubated in the presence of depolarizing KCl (75 mM) solution. Acetylcholine release and peroxidase secretion (a protein secreted by the lacrimal gland) were measured using a spectrofluorometric assay.
RESULTS. Female, but not male, MRL/lpr mouse salivary glands were hyper-responsive to in vivo injection of secretagogues. These mice produced significantly higher amounts of saliva than did age-matched MRL/+ mice. Lacrimal and salivary gland nerves from 18-week-old MRL/+ mice released acetylcholine in response to a depolarizing KCl solution. In contrast, nerves in glands from 18-week-old MRL/lpr mice did not increase acetylcholine release in response to the depolarizing solution. Moreover, lacrimal glands from 18-week-old MRL/+ mice were able to secrete peroxidase in response to a depolarizing KCl solution, whereas those from 18-week-old MRL/lpr could not. This was not due to a defect in the secretory process, because addition of an exogenous secretagogue elicited peroxidase secretion from 18-week-old MRL/lpr as well as MRL/+ mice lacrimal glands.
CONCLUSIONS. The results show that activation of nerves of lacrimal and salivary glands infiltrated with lymphocytes does not increase the release of neurotransmitters, which results in impaired secretion from these glands.
| Introduction |
|---|
|
|
|---|
A decrease in lacrimal and salivary gland secretion is a primary cause of dry eye and dry mouth. Sjögrens syndrome is the leading cause of the aqueous teardeficient type of dry eye.9 10 11 It is an autoimmune disease that occurs almost exclusively in females (>90%). This syndrome is associated with an extensive lymphocytic infiltration of the lacrimal and salivary glands and destruction of epithelial cells.9 10 11 To date there is no cure for this disease. Moreover, the exact cause of Sjögrens syndrome is largely unknown but may involve numerous factors including those of viral, endocrine, neural, genetic, and environmental origin.10 12 13
Several strains of mice have been proposed as models of human Sjögrens syndrome.14 15 16 17 Each of these strains has its advantages and disadvantages. Nonobese diabetic (NOD) mice were first used as a model for type I diabetes. Subsequently, it was found that in these mice, lesions develop in the salivary and lacrimal glands that resemble human Sjögrens syndrome.18 However, the incidence of the lymphocytic accumulation in lacrimal glands in these mice is more frequent and severe in male than in female mice, which is the opposite of that which occurs in humans.19 The New Zealand black (NZB) and hybrid New Zealand black/New Zealand white (NZB/NZW) mice described by Kessler20 and the MRL/l mice and congenic MRL/Mp-lpr/lpr mice first described by Murphy21 were used as models to study another autoimmune disease, systemic lupus erythematosus. Later, it was found that these animals had coexisting Sjögrens syndrome. NZB/NZW and MRL/lpr mice show spontaneous development of a mononuclear cell infiltration of the salivary and lacrimal glands and other organs. The disease in both animals occurs almost exclusively in females (>90%) and develops in an age-dependent manner.14 15 19 MRL/lpr mice, compared with NZB/NZW mice, have more pronounced and destructive mononuclear infiltrates in the lacrimal and salivary glands.16 19
The precise mechanism(s) responsible for the decrease in tear and saliva secretion in Sjögrens syndrome is unknown.10 11 13 It is believed that the dry eye and dry mouth in this disease are due to a progressive lymphocytic infiltration of the lacrimal and salivary glands, an immune-mediated destruction of the epithelial cells, and a consequent decline in tear and saliva production.10 11 13 However, adjacent to the immunopathologic lesions in Sjögrens syndrome, the lacrimal and salivary gland tissues appear to contain normal acinar and ductal epithelia that should be able to secrete enough tears and saliva. One hypothesis could be that a decrease in lacrimal gland innervation and/or an alteration of the signaling pathways of the remaining epithelia accounts for the decreased function of the lacrimal and salivary glands associated with Sjögrens syndrome.
In previous studies, using the MRL/lpr mice, we found that the lymphocytic infiltration of the lacrimal and salivary glands did not alter the parasympathetic, sympathetic, and sensory innervation of the remaining epithelial cells in these tissues.22 We also found that acinar cells isolated from lacrimal and salivary glands of diseased MRL/lpr animals were hyper-responsive to exogenous cholinergic and adrenergic stimulation when compared with age-matched control MRL/+ animals.23 We hypothesized that the exocrine tissues from diseased animals behave as denervated onesthat is, the remaining nerves are not able to release their neurotransmitters, leading to increased responsiveness of these tissues to exogenous stimulation. Another consequence of the impaired release of neurotransmitters is a loss of tear and saliva secretion from lacrimal and salivary glands that leads to dry eye and dry mouth. The purpose of the present studies was to test for this hypothesis.
| Materials and Methods |
|---|
|
|
|---|
Animals
Female and male MRL/MpJ-Fas-lpr/lpr
(MRL/lpr) and MRL/MpJ+/+ (MRL/+) were purchased
from Jackson Laboratories (Bar Harbor, ME). They were maintained in
constant-temperature rooms with fixed lightdark intervals of 12
hours length and were fed ad libitum. All experiments were in
accordance with the ARVO Statement for the Use of Animals in Ophthalmic
and Vision Research and were approved by the Schepens Eye Research
Institute Animal Care and Use Committee.
Histopathology
Lacrimal and submandibular glands were removed from euthanatized
mice and fixed in 4% methanol-free formaldehyde in phosphate-buffered
saline (PBS, containing in millimolar: 137 NaCl, 2.7 KCl, 6.5
Na2HPO4, and 1.5
KH2PO4) for 24 hours at
4°C. After thorough rinsing with PBS, the tissue was dehydrated in
graded alcohol to 95%. The tissue was then infiltrated and embedded in
resin (Historesin; Leica, Deerfield, IL). Sections (3 µm) were placed
on slides and allowed to dry at 60°C. Slides were then stained with
hematoxylin and eosin to check for lymphocytic infiltration of the
lacrimal and salivary glands.
Measurement of Salivary Flow
Total saliva was collected from 4-, 9-, 14-, and 18-week-old
MRL/lpr and MRL/+ mice, mildly anesthetized with a diluted
mixture of ketamine and xylazine, as described by Hu et
al.24
Secretion of saliva was stimulated by
intraperitoneal injection (0.1 ml) of a cocktail containing 0.20 mg
isoproterenol (a ß-adrenergic agonist) plus 0.05 mg pilocarpine (a
cholinergic agonist) per 100 g body weight. The doses of
isoproterenol and pilocarpine used are optimal for stimulating saliva
secretion.24
Five minutes after the injection of the
drugs, saliva was collected continuously over a 10-minute period from
the oral cavity by a micropipette and placed in microcentrifuge tubes.
Care was taken to collect saliva from the same place in the oral
cavity. After a brief centrifugation to remove bubbles, the volume of
saliva was determined using a micropipette. In some experiments, total
salivary protein was determined by the method of
Bradford,25
using bovine serum albumin as the standard.
Potassium-Evoked Release of Acetylcholine and Secretion of
Peroxidase
Lacrimal and submandibular glands were removed from 18-week-old
MRL/lpr and MRL/+ mice. Tissue was cut into small lobules
(
2 mm in diameter), placed in cell strainers, and incubated at
37°C in KrebsRinger bicarbonate buffer (KRB, containing in
millimolar: 120 NaCl, 5 KCl, 1 CaCl2, 1.2
MgCl2, 1.2
KH2PO4, and 25
NaHCO3) supplemented with 10 mM HEPES and 5.5 mM
glucose (pH 7.4). The cell strainers containing lobules were
transferred into fresh KRB solution every 20 minutes for a total of 60
minutes. The lobules were then incubated for 20 minutes in a total
volume of 0.8 ml in normal KRB (referred to as spontaneous release)
then in depolarizing KRB (evoked release) solution where the
concentration of KCl was increased to 75 mM and that of NaCl was
decreased to 55 mM to maintain isotonicity. Both normal and
depolarizing KRB solutions contained neostigmine bromide (0.1 mM), an
inhibitor of acetylcholine esterase, to allow the accumulation of
acetylcholine in the media. In some experiments, lacrimal gland lobules
were further incubated for 20 minutes in 0.8 ml of normal KRB
containing phenylephrine (an
1-adrenergic
agonist, 10-4 M). After
incubation, the media were collected and centrifuged to remove debris.
The lobules were homogenized in 10 mM Tris-HCl (pH 7.5). The amounts of
acetylcholine, choline, and peroxidase in the media and tissue
homogenate were determined using a spectrofluorometric assay.
Spectrofluorometric Assay of Acetylcholine, Choline, and Peroxidase
The amount of acetylcholine, choline, and peroxidase were
measured using the acetylcholine assay kit (Amplex Red; Molecular
Probes). This kit measures the amount of hydrogen peroxide (which in
the presence of horseradish peroxidase leads to the oxidation of Amplex
Red) produced through the oxidation of choline. For the measurement of
acetylcholine and choline, 0.1 ml of media and tissue homogenate were
spotted in duplicate onto 96-well microplates. An acetylcholine and
choline standard curve was used in each experiment. In each well, 0.1
ml of assay buffer (50 mM Tris-HCl, pH 7.5) containing 0.2 M Amplex Red
reagent, 2 U/ml horseradish peroxidase, 0.2 U/ml choline oxidase, and
10 U/ml acetylcholinesterase was added. To measure the amount of
choline, acetylcholinesterase was omitted from the assay buffer. After
incubation, the fluorescence was determined in a fluorescence
microplate reader (model FL600; Bio-Tek, Winooski, VT) using 530 nm
excitation wavelength and 590 nm emission wavelength. The concentration
of choline and acetylcholine was determined using the software provided
by the manufacturer (KC4; Bio-Tek).
For the measurement of peroxidase, 0.1 ml of media and 0.01 ml of tissue homogenate were spotted in duplicate onto 96-well microplates. To each well was added 0.1 ml of assay buffer containing 0.2 M Amplex Red reagent and 0.2 M hydrogen peroxide. After incubation, the fluorescence was determined as described. The amount of secreted peroxidase was expressed as a percentage of the total: (peroxidase in media/peroxidase in media + peroxidase in tissue) x 100.
Data Presentation and Statistical Analysis
Data are expressed as means ± SEM. The data were
statistically analyzed using Students t-test for paired
and unpaired values. Values of P < 0.05 were
considered to be significant.
| Results |
|---|
|
|
|---|
|
|
|
Effect of Disease on Acetylcholine Release
To directly test our hypothesis that the nerves of exocrine
tissues from MRL/lpr are not able to release their
neurotransmitters, we measured the spontaneous and evoked release of
acetylcholine. As shown in Figure 4
, high KCl induced a small but significant release of acetylcholine from
submandibular and lacrimal glands of 18-week-old MRL/+ mice. In
contrast, nerves of submandibular and lacrimal glands from 18-week-old
MRL/lpr mice were not able to release acetylcholine in
response to the depolarizing solution (Fig. 4)
.
|
|
|
These results show that activation, with high KCl, of nerve endings of lacrimal and salivary glands infiltrated with lymphocytes does not increase the release of acetylcholine.
Effect of Disease on Peroxidase Secretion
The main function of the lacrimal gland is to synthesize and
secrete proteins, as well as water and electrolytes, onto the ocular
surface. We have previously shown that secretion of peroxidase can be
induced by exogenous stimulation of lacrimal gland acinar cells with
cholinergic or adrenergic agonists. Figure 7
A shows that KCl-induced depolarization of BALB/c mice lacrimal gland
nerve endings induced a concentration-dependent secretion of
peroxidase. Preincubation of lacrimal gland lobules with atropine
(10-5 M), a cholinergic
muscarinic antagonist, significantly reduced the amount of peroxidase
secreted in response to 75 mM KCl (Fig. 7B)
. These results show that
high KCl-induced peroxidase secretion was due to the activation of
nerve endings and not to a direct effect of KCl on the lacrimal gland
acinar cells. Thus peroxidase secretion can be used as an indirect
index to measure KCl-induced neurotransmitter release from lacrimal
gland nerve endings.
|
|
| Discussion |
|---|
|
|
|---|
-fodrin as a
candidate autoantigen in Sjögrens syndrome. Several studies have shown that intestinal inflammation is accompanied by changes in physiological function that reflect the actions of inflammatory mediators on epithelial cells, muscle cells, and enteric nerves.29 It was found that acetylcholine release from myenteric nerves evoked by electrical field stimulation (EFS) or high KCl solutions was significantly decreased by more than 80% in Trichinella spiralisinfected rats compared with noninfected control rats.30 Similarly, norepinephrine release induced by EFS was decreased by 66% and that induced by KCl was suppressed by 72% in infected rats compared with control noninfected rats.31 In addition to alterations in neurotransmitter release, it was found that the maximum tension generated in vitro by carbachol or serotonin was significantly greater in smooth muscle from inflamed intestine than in control noninflamed intestine,32 suggesting a denervation-like supersensitivity. Thus, it appears that inflammation of the intestine may have two consequences: a blockade of neurotransmitter release and an increased responsiveness of the inflamed tissue to neural agonists, which resembles denervation supersensitivity.
Similar to the inflamed intestine, acinar cells isolated from lacrimal and salivary glands of diseased MRL/lpr animals were previously reported to be hyper-responsive to exogenous cholinergic and adrenergic stimulation when compared with age-matched control MRL/+ animals.23 Moreover, in the present study, we found that MRL/lpr salivary glands were hyper-responsive to in vivo injection of secretagogues, because these mice produced significantly higher amounts of saliva than did age-matched MRL/+ mice. These findings combined with the fact that nerves are still present in the inflamed lacrimal and salivary glands22 led us to hypothesize that these tissues behaved as denervated ones.
In the present study, we showed that stimulation of nerves from inflamed, but not those from noninflamed, lacrimal and salivary glands with high KCl did not increase the release of acetylcholine. Furthermore, we found that, whereas activation of noninflamed lacrimal gland nerves with high KCl resulted in protein secretion, activation of those in inflamed glands did not elicit protein secretion. These findings demonstrate that, as suggested earlier by Sullivan,12 inflammation of exocrine glands in Sjögrens syndrome leads to impaired release of neurotransmitters from nerves and thus to impaired fluid secretion.
What are the mechanisms involved in inflammation-induced
inhibition of neurotransmitter release? Several studies have shown that
suppression of acetylcholine and norepinephrine release from myenteric
nerves was mediated by proinflammatory cytokines including interleukin
(IL)-1ß, IL-6, and tumor necrosis factor
(TNF)-
.33
34
35
36
Moreover, in a rat model of acute
colitis, an inflammatory disease of distal colon, IL-1ß was
implicated in blocking KCl-induced norepinephrine release from the
myenteric plexus.37
IL-1ß has been also shown to
decrease the acetylcholine content of rat hippocampus.36
Another study showed that TNF-
alters neurotransmitter release in
cultured sympathetic neurons.38
IL-1ß and TNF-
were
also implicated in the pathogenesis of acute graft-versus-host disease
(GVHD).39
Based on these studies, inflammation-mediated
production of cytokines seems to inhibit neurotransmitter release, thus
altering the physiology of the inflamed tissues.
Given this abundant literature on the role of proinflammatory cytokines, we hypothesize that concomitant with inflammation of the lacrimal and salivary glands in Sjögrens syndrome, there is an increase in production of cytokines that inhibits neurotransmitter release leading to decreased tear and saliva production from the acinar and ductal cells. In support of this hypothesis, it has been shown that the levels of proinflammatory cytokines are elevated in lacrimal and salivary glands of Sjögrens syndrome patients as well as in animal models.40 41 42 43 Moreover, we found that the protein level of IL-1ß increased, in a disease-dependent manner, in lacrimal and salivary glands of MRL/lpr, but not MRL/+ or BALB/c, mice.44
In summary, our results show that nerves of inflamed lacrimal and salivary glands of MRL/lpr mice are not able to release their neurotransmitters, which results in impaired secretion from these glands.
| Acknowledgements |
|---|
| Footnotes |
|---|
Submitted for publication August 15, 2000; revised October 23, 2000; accepted December 15, 2000.
Commercial relationships policy: N.
Corresponding author: Driss Zoukhri, Department of Ophthalmology, Schepens Eye Research Institute, Harvard Medical School, 20 Staniford Street, Boston, MA 02114. zoukhri{at}vision.eri.harvard.edu
| References |
|---|
|
|
|---|
1-adrenergic agonists is up-regulated in lacrimal and submandibular glands in a murine model of Sjögrens syndrome Clin Immunol Immunopathol 89,134-140[Medline][Order article via Infotrieve]
-fodrin as a candidate autoantigen in primary Sjögrens syndrome Science 276,604-607
suppression of norepinephrine release from rat myenteric plexus Am J Physiol 266,G1123-G1129This article has been cited by other articles:
![]() |
D. Zoukhri, S. Ko, P. C. Stark, and C. L. Kublin Roles of Caspase 1 and Extracellular Signal-Regulated Kinase in Inflammation-Induced Inhibition of Lacrimal Gland Protein Secretion Invest. Ophthalmol. Vis. Sci., October 1, 2008; 49(10): 4392 - 4398. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. S. Vinay, J. D. Kim, T. Asai, B. K. Choi, and B. S. Kwon Absence of 4 1BB Gene Function Exacerbates Lacrimal Gland Inflammation in Autoimmune-Prone MRL-Faslpr Mice Invest. Ophthalmol. Vis. Sci., October 1, 2007; 48(10): 4608 - 4615. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. C. Dias, C. M. Modulo, A. G. Jorge, A. M. Braz, A. A. Jordao Jr, R. B. Filho, J. S. de Paula, and E. M. Rocha Influence of Thyroid Hormone on Thyroid Hormone Receptor {beta}-1 Expression and Lacrimal Gland and Ocular Surface Morphology Invest. Ophthalmol. Vis. Sci., July 1, 2007; 48(7): 3038 - 3042. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. J. Dawson, P. C. Fox, and P. M. Smith Sjogrens syndrome--the non-apoptotic model of glandular hypofunction Rheumatology, July 1, 2006; 45(7): 792 - 798. [Full Text] [PDF] |
||||
![]() |
M. Ramos-Casals and J. Font Primary Sjogren's syndrome: current and emergent aetiopathogenic concepts Rheumatology, November 1, 2005; 44(11): 1354 - 1367. [Full Text] [PDF] |
||||
![]() |
L. J. Dawson, V. L. Caulfield, J. B. Stanbury, A. E. Field, S. E. Christmas, and P. M. Smith Hydroxychloroquine therapy in patients with primary Sjogren's syndrome may improve salivary gland hypofunction by inhibition of glandular cholinesterase Rheumatology, April 1, 2005; 44(4): 449 - 455. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Ding, B. Walcott, and K. T. Keyser Sympathetic Neural Control of the Mouse Lacrimal Gland Invest. Ophthalmol. Vis. Sci., April 1, 2003; 44(4): 1513 - 1520. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |